{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T19:17:36Z","timestamp":1771615056793,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Basic research fund of Beijing Luhe Hospital","award":["20230801"],"award-info":[{"award-number":["20230801"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00428-024-03952-z","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T05:09:57Z","timestamp":1729832997000},"page":"1133-1150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integrating single cell and bulk RNA sequencing data identifies RBM17 as a novel response biomarker for immunotherapy in bladder cancer"],"prefix":"10.1007","volume":"485","author":[{"given":"Bo","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peishan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiangqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangqi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"1","key":"3952_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","volume":"2","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J (2022) Cancer incidence and mortality in China, 2016. J Natl Cancer Cent 2(1):1\u20139. https:\/\/doi.org\/10.1016\/j.jncc.2022.02.002","journal-title":"J Natl Cancer Cent"},{"key":"3952_CR2","doi-asserted-by":"publisher","DOI":"10.2147\/clep.s387289","author":"Z Xiang","year":"2022","unstructured":"Xiang Z, Ye Z, Ma J, Lin Y, Zhou Y (2022) Temporal trends and projections of bladder cancer burden in China from 1990 to 2030: findings from the global burden of disease study. Clin Epidemiol. https:\/\/doi.org\/10.2147\/clep.s387289","journal-title":"Clin Epidemiol"},{"key":"3952_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055","author":"JA Witjes","year":"2020","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G, Hern\u00e1ndez V, Linares Espin\u00f3s E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskim\u00e4e E, Ribal MJ, van der Heijden AG (2020) European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","journal-title":"Eur Urol"},{"key":"3952_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.tps5092","author":"M Nataliya","year":"2020","unstructured":"Nataliya M, Terence WF, Christopher JH, Thomas WF, Mehmet Asim B, Arjun Vasant B, Elizabeth H, Sandy S, Jonathan ER, Daniel Peter P, Earle Frederick B, Jaime RM, Scott TT, Anne-Sophie C, Joyce Leta S, Marya FC, Matthew IM (2020) Study EV-103: new randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.tps5092","journal-title":"J Clin Oncol"},{"key":"3952_CR5","doi-asserted-by":"publisher","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO null n (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. New Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa1817323","DOI":"10.1056\/nejmoa1817323"},{"key":"3952_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03489","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fl\u00e9chon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P (2021) TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.20.03489","journal-title":"J Clin Oncol"},{"key":"3952_CR7","doi-asserted-by":"publisher","unstructured":"Chen M, Yao K, Cao M, Liu H, Xue C, Qin T, Meng L, Zheng Z, Qin Z, Zhou F, Liu Z, Shi Y, An X (2023) HER2-targeting antibody\u2013drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunol Immunother. https:\/\/doi.org\/10.1007\/s00262-023-03419-1","DOI":"10.1007\/s00262-023-03419-1"},{"key":"3952_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00561-4","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O\u2019Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet. https:\/\/doi.org\/10.1016\/s0140-6736(16)00561-4","journal-title":"The Lancet"},{"key":"3952_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236016","author":"M Mancini","year":"2021","unstructured":"Mancini M, Righetto M, Noessner E (2021) Checkpoint inhibition in bladder cancer: clinical expectations, current evidence, and proposal of future strategies based on a tumor-specific immunobiological approach. Cancers. https:\/\/doi.org\/10.3390\/cancers13236016","journal-title":"Cancers"},{"key":"3952_CR10","doi-asserted-by":"publisher","unstructured":"Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee J-L, De Giorgi U, B\u00f6gemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Su\u00e1rez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J, null n (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(20)30541-6","DOI":"10.1016\/s1470-2045(20)30541-6"},{"key":"3952_CR11","doi-asserted-by":"publisher","unstructured":"Powles T, Cs\u0151szi T, \u00d6zg\u00fcro\u011flu M, Matsubara N, G\u00e9czi L, Cheng SYS, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fl\u00e9chon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A, null n (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(21)00152-2","DOI":"10.1016\/s1470-2045(21)00152-2"},{"key":"3952_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.013","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M, Beasley M-B, Borczuk AC, Botling J, Bubendorf L, Chirieac L, Chen G, Chou T-Y, Chung J-H, Dacic S, Lantuejoul S, Mino-Kenudson M, Moreira AL, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Russell PA, Sauter J, Thunnissen E, Wistuba I, Yu H, Wynes MW, Pintilie M, Yatabe Y, Hirsch FR (2018) PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.013","journal-title":"J Thorac Oncol"},{"key":"3952_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.016","author":"DM Vega","year":"2021","unstructured":"Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T, Fabrizio D, Funari V, Newberg J, Bruce LK, Chen S-J, Baden J, Barrett JC, Beer P, Butler M, Cheng J-H, Conroy J, Cyanam D, Eyring K, Garcia E, Green G, Gregersen VR, Hellmann MD, Keefer LA, Lasiter L, Lazar AJ, Li M-C, Macconaill LE, Meier K, Mellert H, Pabla S, Pallavajjalla A, Pestano G, Salgado R, Samara R, Sokol ES, Stafford P, Budczies J, Stenzinger A, Tom W, Valkenburg KC, Wang X, Weigman V, Xie M, Xie Q, Zehir A, Zhao C, Zhao Y, Stewart MD, Allen J (2021) Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.016","journal-title":"Ann Oncol"},{"key":"3952_CR14","doi-asserted-by":"publisher","unstructured":"Li R, Han D, Shi J, Han Y, Tan P, Zhang R, Li J (2020) Choosing tumor mutational burden wisely for immunotherapy: a hard road to explore. Biochimica et Biophysica Acta (BBA) - Rev Cancer. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188420","DOI":"10.1016\/j.bbcan.2020.188420"},{"key":"3952_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.025","author":"L Wang","year":"2019","unstructured":"Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD (2019) Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.025","journal-title":"Eur Urol"},{"key":"3952_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.017","author":"A Maynard","year":"2020","unstructured":"Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG (2020) Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell. https:\/\/doi.org\/10.1016\/j.cell.2020.07.017","journal-title":"Cell"},{"key":"3952_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-01091-3","author":"D Sun","year":"2021","unstructured":"Sun D, Guan X, Moran AE, Wu L-Y, Qian DZ, Schedin P, Dai M-S, Danilov AV, Alumkal JJ, Adey AC, Spellman PT, Xia Z (2021) Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nat Biotechnol. https:\/\/doi.org\/10.1038\/s41587-021-01091-3","journal-title":"Nat Biotechnol"},{"key":"3952_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18916-5","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zhou L, Liu L, Hou Y, Xiong M, Yang Y, Hu J, Chen K (2020) Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-020-18916-5","journal-title":"Nat Commun"},{"issue":"1","key":"3952_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13073-020-0720-0","volume":"12","author":"L Wang","year":"2020","unstructured":"Wang L, Sebra RP, Sfakianos JP, Allette K, Wang W, Yoo S, Bhardwaj N, Schadt EE, Yao X, Galsky MD, Zhu J (2020) A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. Genome Med 12(1):24. https:\/\/doi.org\/10.1186\/s13073-020-0720-0","journal-title":"Genome Med"},{"issue":"7693","key":"3952_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R, Jhunjhunwala S, Banchereau R, Yang Y, Guan Y, Chalouni C, Ziai J, \u015eenbabao\u011flu Y, Santoro S, Sheinson D, Hung J, Giltnane JM, Pierce AA, Mesh K, Lianoglou S, Riegler J, Carano RAD, Eriksson P, H\u00f6glund M, Somarriba L, Halligan DL, van der Heijden MS, Loriot Y, Rosenberg JE, Fong L, Mellman I, Chen DS, Green M, Derleth C, Fine GD, Hegde PS, Bourgon R, Powles T (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548. https:\/\/doi.org\/10.1038\/nature25501","journal-title":"Nature"},{"issue":"9","key":"3952_CR21","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, Zhou M, Nielsen M, Smith AB, Woods M, Hayward MC, Salazar AH, Milowsky MI, Wobker SE, McGinty K, Millburn MV, Eisner JR, Kim WY (2021) Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer 125(9):1251\u20131260. https:\/\/doi.org\/10.1038\/s41416-021-01488-6","journal-title":"Br J Cancer"},{"issue":"1","key":"3952_CR22","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41467-022-33980-9","volume":"13","author":"JS Damrauer","year":"2022","unstructured":"Damrauer JS, Beckabir W, Klomp J, Zhou M, Plimack ER, Galsky MD, Grivas P, Hahn NM, O\u2019Donnell PH, Iyer G, Quinn DI, Vincent BG, Quale DZ, Wobker SE, Hoadley KA, Kim WY, Milowsky MI (2022) Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat Commun 13(1):6658. https:\/\/doi.org\/10.1038\/s41467-022-33980-9","journal-title":"Nat Commun"},{"issue":"2","key":"3952_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H (2018) An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2):400-416.e411. https:\/\/doi.org\/10.1016\/j.cell.2018.02.052","journal-title":"Cell"},{"key":"3952_CR24","doi-asserted-by":"publisher","unstructured":"(2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492):315-322. https:\/\/doi.org\/10.1038\/nature12965","DOI":"10.1038\/nature12965"},{"key":"3952_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-9-3","volume":"9","author":"WJ Kim","year":"2010","unstructured":"Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ, Bae SC (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 9:3. https:\/\/doi.org\/10.1186\/1476-4598-9-3","journal-title":"Mol Cancer"},{"issue":"5","key":"3952_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl G, Abrahamsson J, Holmsten K, Bernardo C, Chebil G, Eriksson P, Johansson I, Kollberg P, Lindh C, L\u00f6vgren K, Marzouka NA, Olsson H, H\u00f6glund M, Ull\u00e9n A, Liedberg F (2022) Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol 81(5):523\u2013532. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.035","journal-title":"Eur Urol"},{"issue":"5","key":"3952_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1158\/1078-0432.Ccr-11-2271","volume":"18","author":"M Riester","year":"2012","unstructured":"Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 18(5):1323\u20131333. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-2271","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3952_CR28","doi-asserted-by":"publisher","first-page":"e38863","DOI":"10.1371\/journal.pone.0038863","volume":"7","author":"D Lindgren","year":"2012","unstructured":"Lindgren D, Sj\u00f6dahl G, Lauss M, Staaf J, Chebil G, L\u00f6vgren K, Gudjonsson S, Liedberg F, Patschan O, M\u00e5nsson W, Fern\u00f6 M, H\u00f6glund M (2012) Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 7(6):e38863. https:\/\/doi.org\/10.1371\/journal.pone.0038863","journal-title":"PLoS ONE"},{"issue":"12","key":"3952_CR29","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.Ccr-12-0077-t","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl G, Lauss M, L\u00f6vgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fern\u00f6 M, Ringn\u00e9r M, M\u00e5nsson W, Liedberg F, Lindgren D, H\u00f6glund M (2012) A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 18(12):3377\u20133386. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-0077-t","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3952_CR30","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","volume":"10","author":"CC Guo","year":"2020","unstructured":"Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, Lee JG, Cogdell D, Zhang M, Yang G, Dadhania V, Choi W, Wei P, Gao J, Theodorescu D, Logothetis C, Dinney C, Kimmel M, Weinstein JN, McConkey DJ, Czerniak B (2020) Assessment of luminal and basal phenotypes in bladder cancer. Sci Rep 10(1):9743. https:\/\/doi.org\/10.1038\/s41598-020-66747-7","journal-title":"Sci Rep"},{"issue":"2","key":"3952_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25(2):152\u2013165. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.009","journal-title":"Cancer Cell"},{"issue":"1","key":"3952_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","volume":"27","author":"H Ogata","year":"1999","unstructured":"Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27(1):29\u201334. https:\/\/doi.org\/10.1093\/nar\/27.1.29","journal-title":"Nucleic Acids Res"},{"key":"3952_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab851","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yao X, Zhou H, Wu X, Tian J, Zeng J, Yan L, Duan C, Liu H, Li H, Chen K, Hu Z, Ye Z, Xu H (2021) OncoSplicing: an updated database for clinically relevant alternative splicing in 33 human cancers. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkab851","journal-title":"Nucleic Acids Res"},{"key":"3952_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw076","author":"A Kahles","year":"2016","unstructured":"Kahles A, Ong CS, Zhong Y, R\u00e4tsch G (2016) SplAdder: identification, quantification and testing of alternative splicing events from RNA-Seq data. Bioinformatics. https:\/\/doi.org\/10.1093\/bioinformatics\/btw076","journal-title":"Bioinformatics"},{"key":"3952_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019","journal-title":"Cell Rep"},{"key":"3952_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-020-0628-4","author":"A Garancher","year":"2020","unstructured":"Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, Moore RA, Mungall AJ, Ma Y, Thiessen N, Li Y, Morcavallo A, Qi L, Kogiso M, Du Y, Baxter P, Henderson JJ, Crawford JR, Levy ML, Olson JM, Cho Y-J, Deshpande AJ, Li X-N, Chesler L, Marra MA, Wajant H, Becher OJ, Bradley LM, Ware CF, Taylor MD, Wechsler-Reya RJ (2020) Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. Nat Neurosci. https:\/\/doi.org\/10.1038\/s41593-020-0628-4","journal-title":"Nat Neurosci"},{"key":"3952_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1356143","author":"A Ling","year":"2017","unstructured":"Ling A, L\u00f6fgren-Burstr\u00f6m A, Larsson P, Li X, Wikberg ML, \u00d6berg \u00c5, Stenling R, Edin S, Palmqvist R (2017) TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. OncoImmunology. https:\/\/doi.org\/10.1080\/2162402x.2017.1356143","journal-title":"OncoImmunology"},{"key":"3952_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01600-6","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, Buchschacher GL, Alekseev B, Mellado B, Karaszewska B, Doss JF, Rasuo G, Datye A, Mariathasan S, Williams P, Sweeney CJ (2022) Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-021-01600-6","journal-title":"Nat Med"},{"key":"3952_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.09.041","author":"A De Maio","year":"2018","unstructured":"De Maio A, Yalamanchili HK, Adamski CJ, Gennarino VA, Liu Z, Qin J, Jung SY, Richman R, Orr H, Zoghbi HY (2018) RBM17 interacts with U2SURP and CHERP to regulate expression and splicing of RNA-processing proteins. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2018.09.041","journal-title":"Cell Rep"},{"key":"3952_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31155-0","author":"L Liu","year":"2022","unstructured":"Liu L, Vujovic A, Deshpande NP, Sathe S, Anande G, Chen HTT, Xu J, Minden MD, Yeo GW, Unnikrishnan A, Hope KJ, Lu Y (2022) The splicing factor RBM17 drives leukemic stem cell maintenance by evading nonsense-mediated decay of pro-leukemic factors. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-022-31155-0","journal-title":"Nat Commun"},{"key":"3952_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02024-3","author":"L Han","year":"2021","unstructured":"Han L, Lai H, Yang Y, Hu J, Li Z, Ma B, Xu W, Liu W, Wei W, Li D, Wang Y, Zhai Q, Ji Q, Liao T (2021) A 5\u2032-tRNA halve, tiRNA-Gly promotes cell proliferation and migration via binding to RBM17 and inducing alternative splicing in papillary thyroid cancer. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-021-02024-3","journal-title":"J Exp Clin Cancer Res"},{"key":"3952_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234062","author":"C Li","year":"2020","unstructured":"Li C, Ge S, Zhou J, Peng J, Chen J, Dong S, Feng X, Su N, Zhang L, Zhong Y, Deng L, Tang X (2020) Exploration of the effects of the CYCLOPS gene RBM17 in hepatocellular carcinoma. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0234062","journal-title":"PLoS ONE"},{"key":"3952_CR43","doi-asserted-by":"publisher","unstructured":"Kahles A, Lehmann K-V, Toussaint NC, H\u00fcser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, null n, R\u00e4tsch G (2018) Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2018.07.001","DOI":"10.1016\/j.ccell.2018.07.001"},{"key":"3952_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.02.016","author":"Y Li","year":"2017","unstructured":"Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z, He J (2017) Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2017.02.016","journal-title":"Cancer Lett"},{"key":"3952_CR45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1802415115","author":"L Fan","year":"2018","unstructured":"Fan L, Zhang F, Xu S, Cui X, Hussain A, Fazli L, Gleave M, Dong X, Qi J (2018) Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells [Biochemistry]. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/pnas.1802415115","journal-title":"Proc Natl Acad Sci USA"},{"key":"3952_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/nature10662","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. https:\/\/doi.org\/10.1038\/nature10662","journal-title":"Nature"},{"key":"3952_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14690","author":"C Wang","year":"2020","unstructured":"Wang C, Weng M, Xia S, Zhang M, Chen C, Tang J, Huang D, Yu H, Sun W, Zhang H, Lai M (2020) Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer. Cancer Sci. https:\/\/doi.org\/10.1111\/cas.14690","journal-title":"Cancer Sci"},{"key":"3952_CR48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180870","author":"B Gong","year":"2019","unstructured":"Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, Besse B, Yanagitani N, Friboulet L, Nishio M, Takeuchi K, Kawamoto H, Fujita N, Katayama R (2019) Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20180870","journal-title":"J Exp Med"},{"key":"3952_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4239","author":"AC Smart","year":"2018","unstructured":"Smart AC, Margolis CA, Pimentel H, He MX, Miao D, Adeegbe D, Fugmann T, Wong K-K, Van Allen EM (2018) Intron retention is a source of neoepitopes in cancer. Nat Biotechnol. https:\/\/doi.org\/10.1038\/nbt.4239","journal-title":"Nat Biotechnol"},{"key":"3952_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24879-y","author":"K Fukumura","year":"2021","unstructured":"Fukumura K, Yoshimoto R, Sperotto L, Kang H-S, Hirose T, Inoue K, Sattler M, Mayeda A (2021) SPF45\/RBM17-dependent, but not U2AF-dependent, splicing in a distinct subset of human short introns. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-021-24879-y","journal-title":"Nat Commun"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03952-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03952-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03952-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T13:09:54Z","timestamp":1734959394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03952-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3952"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03952-z","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the clinical ethics committee of Beijing Luhe Hospital, Capital Medical University. All patients had signed informed consent. This study complied with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not appliable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}